Lifecore Biomedical Inc. (LFCR)
LFCR trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$6.42
-0.31% on the day
Market cap
$243.0M
Micro cap
Revenue · 2025
$128.9M
No prior year to compare
Net income · 2025
-$38.7M
-30.0% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 10-KT (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), period ending 2025-05-25, https://www.sec.gov/Archives/edgar/data/1005286/000100528626000009/0001005286-26-000009-index.htm. Net income: SEC 10-KT (us-gaap:NetIncomeLoss), period ending 2025-05-25.
Profile
| Field | Value |
|---|---|
| Ticker | LFCR on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001005286 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $128.9M |
| Net income | -$38.7M |
| Operating income | Not in SEC XBRL data |
| Net margin | -30.0% |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | $17.5M |
| Total assets | $232.2M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1.9× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2025-09-30 |
| Latest annual report | 10-KT | 2026-03-16 |
| Latest quarterly / interim | 10-Q | 2026-08-05 |
| Latest current report | 8-K | 2026-09-29 |
| Latest proxy DEFA 14A | DEFA14A | 2026-09-28 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ACIU | AC Immune SA | $2.40 | -2.04% | $244.3M |
| AMRN | Amarin Corporation plc | $11.58 | +0.43% | $244.6M |
| QTTB | Q32 Bio Inc. | $8.06 | -7.78% | $239.9M |
| VOGX | Vogenx Inc | $16.76 | -2.22% | $249.0M |
| BBOT | BridgeBio Oncology Therapeutics Inc. Common Stock | $2.95 | -9.51% | $236.5M |
| RCKT | Rocket Pharmaceuticals Inc. | $2.30 | -7.26% | $252.5M |
| BCYC | Bicycle Therapeutics plc | $3.63 | -4.47% | $254.1M |
| BIOA | BioAge Labs Inc. | $5.57 | -6.23% | $255.6M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier